Judge Nixes Abbott's Patent Defense In Norvir Case

By Brendan Pierson

Law360, New York (May 20, 2008, 12:00 AM ET) -- A judge knocked out a major part of Abbott Laboratories' defense against an antitrust suit related to its HIV treatment Norvir, ruling Friday that claims in two of Abbott's patents for a method of combining Norvir with other protease inhibitors are invalid.

Judge Claudia Wilken of the U.S. District Court for the Northern District of California also ruled that plaintiffs in the suit cannot seek damages under state common law but could seek injunctive relief under federal antitrust law. She also said that California plaintiffs could...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles